Review Article
Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer’s Disease
Table 4
Summary of DHA/EPA dietary intervention trials in patients with Alzheimer’s disease (AD) in the last 10 years.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AA = arachidonic acid; DHA = docosahexaenoic acid; EPA = eicosapentaenoic acid; DAD = Disability Assessment for Dementia Scale; CGB = Caregiver Burden Scale; MADRS = Montgomery-Asberg Depression Rating Scale; NPI = Neuropsychiatric Inventory; MMSE = Minimental State Examination; ADAS-cog. = Cognitive Portion of the Alzheimer’s Disease Assessment Scale; CIBIC plus = Clinician’s Interview-Based Impression of Change Scale; RBANS = Repeatable Battery for the Assessment of Neuropsychological Status; NS = Nonsignificant; MRI = Magnetic Resonance Imaging; CDR = Clinical Dementia Rating. |